Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) EV-to-EBIT : -30.70 (As of May. 28, 2024)

Provectus Biopharmaceuticals EV-to-EBIT Chart

Provectus Biopharmaceuticals Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial					-7.94	-9.53	-5.28	-14.04	-14.98

Provectus Biopharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-22.64	-17.18	-12.91	-14.98	-31.34

Competitive Comparison of Provectus Biopharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, Provectus Biopharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provectus Biopharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's EV-to-EBIT falls into.

Provectus Biopharmaceuticals EV-to-EBIT Calculation

Provectus Biopharmaceuticals's EV-to-EBIT for today is calculated as:

Provectus Biopharmaceuticals's current Enterprise Value is $78.28 Mil.
Provectus Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals  (OTCPK:PVCT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Provectus Biopharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Provectus Biopharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $79.91 Mil.
Provectus Biopharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Provectus Biopharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Provectus Biopharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Provectus Biopharmaceuticals (Provectus Biopharmaceuticals) Business Description